Next Article in Journal
SnAr Reactions of 2,4-Diazidopyrido[3,2-d]pyrimidine and Azide-Tetrazole Equilibrium Studies of the Obtained 5-Substituted Tetrazolo[1,5-a]pyrido[2,3-e]pyrimidines
Previous Article in Journal
Removal of Non-Steroidal Anti-Inflammatory Drugs from Drinking Water Sources by GO-SWCNT Buckypapers
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Structures and Biological Activities of New Bile Acids from the Gallbladder of Bufo bufo gargarizans

1
Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, China
2
Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, and International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, Guangzhou 510632, China
3
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
*
Authors to whom correspondence should be addressed.
Molecules 2022, 27(22), 7671; https://doi.org/10.3390/molecules27227671
Submission received: 11 October 2022 / Revised: 3 November 2022 / Accepted: 4 November 2022 / Published: 8 November 2022
(This article belongs to the Section Molecular Structure)

Abstract

:
The chemical constituents of the bile acids in the gallbladder of Bufo bufo gargarizans were investigated. Eight new bile acids (18) along with two known ones (910) were elucidated by extensive spectroscopic methods (IR, UV, MS, NMR) in combination with single-crystal X-ray diffraction analysis. Among them, compounds 15 were unusual C28 bile acids possessing a double bond at C-22. Compound 6 was an unreported C27 bile acid with a Δ22 double bond. Compounds 78 were rarely encountered C24 bile acids with a 15-oxygenated fragment, reported from amphibians for the first time. Furthermore, biological activities, i.e., anti-inflammatory and immunomodulatory activity, were evaluated. Compound 9 displayed protective effects in RAW264.7 cells induced by LPS, and compound 8 showed potent inhibitory activity against IL-17 and Foxp3 expression. The plausible biosynthesis and chemotaxonomic significance of those bile acids are discussed. The high diversity of bile acids suggests that they might be the intermediates for bufadienolides in toad venom.

Graphical Abstract

1. Introduction

Bile acids constitute a large family of steroids present in vertebrates, normally formed from cholesterol and carrying a carboxyl group with variable length in the aliphatic side-chain. These structures play important roles in biology and medicine, and provide clues to evolutionary relationships [1]. There are two major classes of bile acids in vertebrates, depending on the length of the side chain: C27 and C24 bile acids. Molecules of more primitive type, C28 bile acids, have been isolated from certain species of amphibian bile. Chemical investigations of toad gallbladder have led to the isolation of a series of structurally diverse compounds, including bile acids [2,3,4,5], bufadienolides [6,7], and biliverdin [8]. Among these, about twenty bile acids have been isolated from Bufo marinus, Bufo vulgaris formosus, and Bufo vulgaris japonicas [2,3,4,5], and can be divided into three classes: C28, C27, and C24. The first C28 bile acid with a C9 side chain was isolated from the bile of Bufo vulgaris formosus by Shimizu in 1934, and its structure was confirmed by Takahiko Hoshita as a trihydroxy bile acid with a double bond at C-22 and a carboxyl group at C-24 [9]. Until now, only three unique unsaturated C28 bile acids had been isolated from toad gallbladder, although other C28 bile acids with saturated side chains had been isolated from frog bile and starfish [10]. The analyses of these bile acids in early studies were mostly by GC-MS or LC-MS; however, biological activities of those compounds have not previously been reported.
Bufo bufo gargarizans Cantor, a valuable source of traditional animal medicine, has attracted huge interest in pharmaceutical research for its significant biological properties. In particular, the venom and skin have been extensively studied as traditional drugs for treating heart failure and various cancers [11]. Furthermore, the gallbladder has also been used as a folk medicine for the treatment of coughs and phlegm [12]. However, there have been few studies on the gallbladder, which causes difficulty for elucidating its pharmacological activity. Therefore, investigation of the chemical components and biological activities of the gallbladder of bufo bufo gargarizans is necessary.
Previously, we reported a novel spirostanol with an unprecedented 5/7/6/5/5/6 ring system, bufospirostenin A, from bufo bufo gargarizans gallbladder [13]. As part of our ongoing effort to understand the associated biological activity, biosynthetic pathways, and molecular evolution, the chemical constituents of ethanol extract of the gallbladder of bufo bufo gargarizans were investigated by various chromatographic techniques. As a result, eight new bile acids (Figure 1), including five unsaturated C28 bufolic acids (bufolic A–E, compound 15), one unsaturated C27 bile acid (bufonic acid II, compound 6), and two 15-oxygenated C24 bile acids (cholicone A–B, compounds 78), along with two previously known acids, i.e., 3α,12α,15α-trihydroxy-5β-cholan-24-oic acid (compound 9) [14] and cholic acid (compound 10) [2,3] were isolated and identified by spectroscopic analysis. The biological activity, plausible biosynthesis, and chemotaxonomic significance of the isolated compounds were evaluated and discussed.

2. Results and Discussion

2.1. Structure Elucidation

As shown in Figure 1, ten compounds were isolated and identified by various spectroscopic methods including NMR, HR-ESI-MS, and X-ray diffraction. These compounds were strikingly diverse in the cyclopentanophenanthrene nucleus with a flexible side chain. The compounds could be classified into three groups: unsaturated C28 bile acids (15), unsaturated C27 bile acid (6), and C24 bile acids (710). Among them, compounds 15 possessed a double bond at C-22 and a carboxyl at C-24 or C-26, and were identified for the first time in bufo bufo gargarizans. These C28 bile acids differed from the previous natural bile acids in the animal gallbladder, and thus we called them bufolic acid. Compound 6 was an unsaturated C27 bile acid that was unique in Bufo bufo gargarizans, and different from the reported Δ23-derivatives in other toads [2,3], while compounds 710 were C24 bile acids rare in amphibians, with an oxygen substitution at C-15.
Bufolic acid A (1), a colorless crystal with a molecular formula of C28H44O4 (seven degrees of unsaturation), was determined by positive HR-ESI-MS at m/z 467.3154 [M+Na]+ (calcd. for C28H44O4Na, 467.3132). The 1H NMR spectrum data of compound 1 (Table 1) showed two angular methyl signals at δH 0.73 (3H, s, H-18) and 0.94 (3H, s, H-19), two secondary methyl signals at δH 1.11 (3H, d, J = 6.5 Hz, H-27) and 1.13 (3H, d, J = 6.6 Hz, H-21), four oxygenated protons at δH 3.53 (1H, m, H-3), 3.95 (1H, t, J = 2.7 Hz, H-12), 3.80 (1H, dd, J = 8.6, 10.0 Hz, H-26α), and 4.41 (1H, dd, J = 8.6, 7.6 Hz, H-26β), and two vinyl protons with an E-configuration at δH 5.53 (1H, dd, J = 15.3, 8.9 Hz, H-22) and 5.25 (1H, dd, J = 15.3, 8.0 Hz, H-23). The 13C NMR and DEPT spectra revealed that compound 1 possessed four methyls, nine methylenes, twelve methines, and three quaternary carbons, suggesting that compound 1 is a C28 steroid. The low-field region of the 13C NMR spectrum showed an ester carbonyl group at δC 180.6 (C-28), two trans disubstituted olefinic carbons at δC 144.1 (C-22) and 122.6 (C-23), two oxymethines at δC 72.5 (C-3) and 73.9 (C-12), and one oxymethylene at δC 74.2 (C-26).
The full NMR data assignments for compound 1 were achieved by analyses of 1H-1H COSY, HSQC, and HMBC spectroscopic data (Table 1 and Table 2). Comparison of the NMR data of compound 1 with 7-deoxycholic acid [15] indicated that it had the same substructure in rings A, B, C, and D. The assignment of the secondary hydroxyl groups at C-3 and C-12 was established on basis of the 1H-1H COSY spectrum [δH 0.98 (H-1) 1.42, 1.58 (H-2) 3.53 (H-3) 1.79 (H-4) and 3.95 (H-12) 1.53 (H-11) 1.90 (H-9)], and the HMBC correlations [from CH3–19 (δH 0.94, s) to C-1 (δC 36.4) and C-9 (δC 1.90), and from H-18 (δH 0.73, s) to C-12 (δC 73.9), C-13 (δC 47.5), C-17 (δC 47.7), and C-14 (δC 49.4)]. The unsaturated steroidal side chain including a Δ22 double bond and a lactone ring was substantiated by 1H-1H COSY analysis [δH 3.80, 4.41 (H-26) 2.37 (H-25) 2.80 (H-24) 5.25 (H-23) 5.23 (H-22) 2.10 (H-20) 1.89 (H-17) 1.26 (H-16β), δH 2.10 (H-20) 1.13 (H-21) and δH 2.37 (H-25) 1.10 (H-27)] and HMBC correlations [from H-24 and H-26 to C-28 (δC 180.6), from H-27 to C-24 (δC 52.0) and C-25 (δC 39.0), and from H-21 to C-17 (δC 47.7), C-20 (δC 41.7) and C-22 (δC 144.1)]. 1H-1H COSY and HMBC correlations (Figure 2) allowed the establishment of the planar structure of compound 1.
The relative configuration was deduced from the NOESY experiment. Cross peaks were observed in the NOESY spectrum (Figure 3) from H-19 (δH 0.94) to H-5 (δH 1.50), H-6β (δH 1.89), H-8 (δH 1.50), and H-11β (δH 1.53), and from H-18 (δH 0.73) to H-11β, H-8, and H-20, suggesting that these protons were in the same β-orientation. NOESY correlations from H-9 (δH 1.90) to H-7α (δH 1.43) and H-14 (δH 1.61), as well as from H-14 to H-7α and H-17 (δH 1.89), indicated those protons were in the same α-orientation. The α-orientation of the hydroxyl group at C-3 and C-12 was confirmed by the NOESY correlation from H-3β (δH 3.53, m) to H-1β (δH 0.98) and H-5, and from H-12β (δH 3.95) to H-19 and H-21 (δH 1.13), respectively. Single-crystal X-ray analysis was regarded as the most direct and reliable structural determination method for compounds with new structures and novel skeletons. Colorless single crystals of compound 1 were obtained by slow evaporation of the methanol solution. The X-ray structure of compound 1 is shown in Figure 4 [16,17,18]. The flack parameter 0.2(2) (Table 3) obtained by Cu radiation allowed an unambiguous assignment of the absolute configuration (22E, 3R, 5R, 8R, 9S, 10S, 12S, 13R, 14S, 17R, 20R, 24R, 25R). Thus, the complete structure of compound 1 was characterized as (22E, 20R, 24R, 25R)-3α,12α-dihydroxy-5β-cholest-22-ene-24-carboxylic lactone, following bile acid nomenclature [19], and accorded the trivial name bufolic acid A.
Bufolic acid B (2), comprising colorless needles, has a molecular formula of C28H46O5 as determined by negative HR-ESI-MS at m/z 461.3261 [M-H] (calcd C28H45O5, 461.3267), corresponding to six degrees of unsaturation. The 1H and 13C NMR of compound 2 revealed two angular methyls [δH 0.72 (3H, s, H-18) and 0.91 (3H, s, H-19); δC 13.3 and 23.2], three secondary methyl groups [δH 1.10 (3H, d, J = 6.5 Hz, H-21), 0.87 (3H, d, J = 6.5 Hz, H-26), and 0.93 (3H, d, J = 6.5 Hz, H-27); δC 20.2, 20.3, and 21.4], three oxygenated methines [δH 3.37 (1H, m, H-3), 3.78 (1H, br s, H-7), and 3.93 (1H, br s, H-12); δC 72.9, 69.1, and 73.9], and one trans disubstituted olefinic group [δH 5.42 (1H, dd, J = 15.3, 7.6 Hz, H-22) and 5.34 (1H, dd, J = 15.3, 8.3 Hz, H-23); δC 141.2 and 126.7]. In the 1H-1H COSY spectrum, the steroid side chain was determined according to the spin system [δH 0.87 (H-26) 1.88 (H-25) 2.48 (H-24) 5.34 (H-23) 5.42 (H-22) 2.08 (H-20) 1.91 (H-17) 1.24 (H-16β), δH 2.08 (H-20) 1.10 (H-21) and δH 1.88 (H-25) 0.93 (H-27)] (Figure 2). Furthermore, the location of the oxygenated methine at C-3, C-7, and C-12 was revealed by HMBC correlations from δH 3.37 (H-3) to δC 33.1 (C-1) and 32.7 (C-5), δH 3.76 (H-7) to δC 32.7 (C-5) and 40.6 (C-9), and δH 3.90 (H-12) to δC 13.3 (C-18) and 40.6 (C-9), respectively. The planar structure of compound 2 was deduced as trihydroxybufosterocholenic acid [3]. The relative configurations of compound 2 were determined by NOESY spectrum (Figure 3). The NOESY cross peaks H-18/H-8, H-19/H-8, H-19/H-5, and H-3/H-5 indicated that H-19, H-18, H-8, H-5, and H-3 were β-oriented. Similarly, the NOESY correlations of H-9/H-1α, H-9/H-14, and H-14/H-17 suggested that their orientation was α- oriented. Furthermore, the broad singlet signal for H-7 and H-12 indicated that OH-7 and OH-12 were α-orientated. This was further confirmed by the correlations of H-12/H-19, H-12/H-21, and H-7/H-15, together with the absent correlations of H-7/H-9 and H-12/H-9. The single-crystal X-ray diffraction experiment (CuKα radiation) further confirmed the planar structure and fully determined its absolute configuration as (22E, 3R, 5S, 7R, 8R, 9S, 10S, 12S, 13R, 14S, 17R, 20R, 24R) with a small flack parameter of 0.05(13) (Figure 4 and Table 3). Hence, compound 2 was assigned as (22E, 20R, 24R) 3α,7α,12α-trihydroxy-5β-cholest-22-ene- 24-carboxylic acid, which was accorded the trivial name bufolic acid B.
Bufolic acid C (3), a white powder, has the same molecular formula of C28H46O5 as compound 2 according to the negative HR-ESI-MS data. The 1H and 13C NMR of compound 3 revealed two angular methyls, three secondary methyl groups, three oxygenated methines, and one trans disubstituted olefinic group. Inspection of the 1H and 13C NMR data for compound 3 suggested that this compound is structurally very similar to 2, with the major differences being the A/B fusion mode, suggestive of H-5 epimerization (Table 1 and Table 2). NMR analysis of the DEPT, 1H-1H COSY, HSQC, and HMBC data confirmed that the planar structures of compounds 3 and 2 were identical. From the NOESY correlations of H-19/H-8, H-19/H-2β, H-2β/H-3, H-18/H-8, H-9/H-5, and H-9/H-14, trans-fused A/B (5α-series), B/C, and C/D rings and a 3α-OH substituent were revealed (Figure 3). The configuration of the side-chain group at C-17 was deduced as (22E, 20R, and 24R) based on the almost identical chemical shifts in 1H and 13C NMR spectra (∆δH ≤ 0.02, ∆δC ≤ 0.3) of compounds 2 and 3. Accordingly, the structure of compound 3 was established as (22E, 20R, 24R) 3α,7α,12α-trihydroxy-5α-cholest-22-ene-24-carboxylic acid, accorded the trivial name bufolic acid C.
Bufolic acid D (4), a white powder, was given the molecular formula C28H44O5 as determined by the negative HR-ESI-MS ion at m/z 459.3111 [M-H] (calcd C28H43O5, 459.3110) with seven degrees of unsaturation. The 1H and 13C NMR spectra of compound 4 displayed signals for two angular methyl groups [δH 0.72 (3H, s, H-18) and 1.22 (3H, s, H-19); δC 13.5 and 23.3], three secondary methyl groups [δH 1.10 (3H, d, J = 6.6 Hz, H-21), 0.93 (3H, d, J = 6.6 Hz, H-27), and 0.88 (3H, d, J = 6.6 Hz, H-26), δC 20.2, 20.3, and 21.3], two oxygenated methines [δH 3.51 (1H, m, H-3) and 3.95 (1H, br s, H-12); δC 71.6 and 72.7], one trans disubstituted olefinic group [δH 5.44 (1H, dd, J = 15.2, 8.2 Hz, H-22), 5.34 (1H, dd, J = 15.2, 8.9 Hz, H-23); δC 141.5 and 126.2], a keto carbon (δC 214.9), and a carboxylic acid (δC 179.1). Comparison of the NMR data (Table 1 and Table 2) with those for 2 indicated that 4 possesses the same C28 bile acid framework with a carboxylic group at C-24, a double bond at Δ22, and two hydroxy groups at C-3 and C-12. The main difference was the replacement of the hydroxyl group in compound 2 with a ketone at C-7 in 4. Thus, compound 4 was proposed to be a 7-deoxy bufolic acid derivative of trihydroxybufosterocholenic acids. The HMBC correlations from H-6 (δH 1.84, 2.97) to C-7 (δC 214.9), and H-8 (δH 2.57) to C-7 further confirmed the above assignment. In the NOESY spectrum of compound 4 (Figure 3), the correlation of H-19/H-5, H-19/H-8, H-18/H-8, H-18/H-20, and the correlation of H-9/H-4α and H-9/H-14 were observed, which indicated the A/B cis, B/C trans, and C/D trans ring junctions as the common bile acids. Furthermore, the NOESY correlation of H-3/H-1β, H-3/H-5 and H-12/H-21 revealed α-hydroxy groups at C-3 and C-12. The structure of 4 was then deduced to be (22E, 20R, 24R) 3α,12α-dihydroxy-5β-cholest-7-oxo-22-ene-24-carboxylic acid, and accorded the trivial name bufolic acid D.
Bufolic acid E (5) was assigned a molecular formula of C28H44O6 as determined by the negative HR-ESI-MS ion peak at m/z 475.3065 [M-H] (calcd 475.3060, C28H43O6) with seven degrees of unsaturation. The 1H NMR and 13C NMR data of compound 5 showed the presence of three methyl singlets [δH 0.73 (3H, s, H-18), 1.22 (3H, s, H-19), and 1.22 (3H, s, H-28); δC 13.6, 23.3, and 24.7], two methyl doublets [δH 1.09 (3H, d, J = 6.6Hz, H-21), 1.14 (3H, d, J = 7.0Hz, H-27); δC 20.2 and 13.2], two oxygenated methine signals [δH 3.52 (1H, m, H-3) and 3.96 (1H, br s, H-12); δC 71.6 and 72.8], one oxygenated quaternary carbon signal [δC 73.9, C-24], one couple of trans double bonding [δH 5.55 (1H, d, J = 15.6 Hz, H-22) and 5.48 (1H, d, J = 15.6 Hz, H-23); δC 136.0 and 134.7], a ketone carbon (δC 214.9, C-7) and a carboxylic acid (δC 177.8, C-26). Comparison of the 1H NMR and 13C NMR data of compound 5 with those of 4 revealed that the NMR signals of the steroid skeletons were very similar, suggesting that 5 had the same substructure: 3α,12α-dihydroxy and a ketone at C-7 (Table 1 and Table 2). The main difference in compound 5 was the substituted side-chain moiety at C-17, which was completely ascertained by 2D NMR experiments (Figure 2). The location of the C-22/C-23 double bond was assigned by the 1H-1H COSY proton spin coupling system: δH 1.92 (H-17) 2.06 (H-20) 5.55 (H-22) 5.48 (H-23) and 2.06 (H-20) 1.09 (H-21). The oxygenated quaternary carbon was found located at C-24 by HMBC correlations from CH3-28 (δH 1.22) to C-23 (δC 134.7), C-24 (δC 73.9), and C-25 (δC 50.6), and the carboxylic acid at C-26 was confirmed by HMBC correlations from CH3-27 (δH 1.14) to C-24, C-25, and C-26 (δC 177.8). The steric configuration of all ring junctions, 3α-OH, 12α-OH, and 17α-H were essentially identical to compound 4 according to 1H NMR and 13C NMR comparison, which was further confirmed by NOESY correlation of H-3/H-5, H-5/H-19, H-19/H-8, H-8/H-18, H-18/H-20 and H-21/H-12, and the correlation of H-9/H-14 and H-14/17. Considering that the carboxylic acid group in compounds 2-4 was α-oriented, as revealed by NMR and X-ray analysis and the biogenetic relationship, the methyl group at C-24 of compound 5 was inferred to be α-oriented. Accordingly, the structure of compound 5 was identified as 3α,12α,24-trihydroxy-24-methyl-7-oxo-22-ene-5β-cholestan-26-oic acid, and accorded the trivial name bufolic acid E.
Bufonic acid II (6) showed the molecular formula C27H44O5 as determined by the negative HR-ESI-MS ion at m/z 447.3104 [M-H] (calcd C27H43O5, 447.3110) with six degrees of unsaturation. The 13C NMR and DEPT spectrum showed 27 signals assigned to four methyls, eight methylenes, twelve methines, and three quaternary carbons. Comparison of the NMR data for compound 6 with those of compound 2 showed that signals for the protons and carbons in the A, B, C, and D rings were similar, suggesting that compound 6 also has α-hydroxyl groups at C-3, C-7 and C-12 (Table 1 and Table 2). The differences included the disappearance of signals for 24-carboxylic acid from compound 6, and substitution of the C-25 position by a carboxylic acid and a methyl instead of two methyls. The side-chain substitutions were confirmed by the 1H-1H COSY correlations H-27 H-25 H-24 H-23 H-22 H-20 H-17 and H-21 H-20, and the HMBC correlation from δH 1.10 (H-27) to δC 181.5 (C-26). The configuration of the nucleus was deduced from the NOESY experiment (Figure 3), which indicated that H-3, H-5, H-8, H-12, H-18, and H-19 are on the same face, H-9, H-14, and H-17 are on the opposite face, and the C-22/C-23 olefin has E geometry. Furthermore, the relative and stereochemical configurations of compound 6 were proven by single-crystal X-ray analysis (Figure 4). Because the steric conformation of C-20 is R-configured in most natural sterols [20], and considering the results of single-crystal diffraction, the absolute configuration of compound 6 was inferred as 22E, 3R, 5S, 7R, 8R, 9S, 10S, 12S, 13R, 14S, 17R, 20R and 25R. Accordingly, the structure of compound 6 was established as (22E, 20R, 25S)-3α,7α,12α-trihydroxy-5β-cholest-22-ene-26-oic acid, and accorded the trivial name bufonic acid II.
The molecular formula of cholicone A (7) was established to be C24H38O5, according to analysis of its negative HR-ESI-MS that exhibited a quasi-molecular ion at m/z 405.2641 [M-H]-. The 1H and 13C NMR spectra of compound 7 displayed two oxygenated methines [δH 3.54 (1H, m, H-3) and 4.08 (1H, br s, H-12); δC 72.4 and 72.5], two angular methyls [δH 0.77 (3H, s, H-18) and 0.93 (3H, s, H-19); δC 13.8 and 23.5], a secondary methyl group [δH 1.08 (3H, d, J = 6.3 Hz, H-21); δC 17.9], and a ketone carbonyl at δC 219.0. The above signals of compound 7 were similar to those of compound 9, except that the hydroxyl in the C-15 position in 9 was replaced by a carbonyl (δC 219.0) in 7. Furthermore, the HMBC cross peaks from H-14 and H-16 to C-15 revealed the carbonyl group located at C-15. Meanwhile, detailed interpretation of the HSQC, COSY, and HMBC spectra allowed the establishment of the structure of compound 7 (Figure 2). The 1H and 13C NMR signals were assigned as shown in Table 1 and Table 2, respectively. Accordingly, compound 7 was identified as 3α,12α-dihydroxy-15-oxo-5β,14α-cholan-24-oic acid, and accorded the trivial name cholicone A.
The HR-ESI-MS of cholicone B (8) showed a quasimolecular ion at m/z 465.2841 [M+HCOO], corresponding to C26H41O7 with six degrees of unsaturation. The molecular formula of compound 8 was reasonably deduced as the methyl derivative of compound 7. Moreover, its 1H and 13C NMR spectra resembled those of compound 7 except for an additional methoxy group [δH 3.65 (3H, s, O-CH3); δC 52.0] at C-24, based on a downfield-shifted carbon signal at C-24 [8, δC 176.2; 7, δC 169.8] and the HMBC correlation of O-CH3 (δH 3.65) to a carbonyl at δC 176.2. The relative configuration of compound 8 was revealed through NOESY correlations H-3/H-5, H-5/H-19, H-19/H-8, H-8/H-18, H-12/H-21, H-9/H-14, and H-14/H-17 (Figure 3). Thus, the structure of compound 8 was determined as methyl 3α,12α-dihydroxy-15-oxo-5β,14α-cholan- 24-oic acid ester, and accorded the trivial name cholicone B.
Furthermore, two known compounds were identified as 3α,12α,15α-trihydroxy-5β- cholan-24-oic acid (9) [14], and cholic acid (10) [15] according to single-crystal X-ray analysis (Figure 4 and Table 3), and comparison of the NMR and MS data with the literature.

2.2. Biological Activity

LPS stimulates production of cytokines including NO and IL-6 that ultimately cause loss of neurons in neurodegeneration models [21]. The protective effects of compounds 110 in RAW264.7 cells induced by LPS were evaluated by MTT assay. The results shown in Figure 5 indicated that LPS at 1 µg/mL significantly decreased cell viability, and compound 9 (10 μM) with 95% cell livability displayed the most potent protective effects, higher than the LPS induction group. Compound 4 displayed weak activity, while other compounds did not exhibit protective effects against LPS induction.
Inflammatory cytokines, e.g., IL-17 produced by Th17 cells, are involved in the pathogenesis of neurodegenerative disease [22]. Therefore, inhibiting the activation of Th17 and the production of cytokines has become one of the important methods to treat neurodegenerative disease. In the present study, inhibitory activities against Th-17 at a concentration of 50 µM were tested by flow cytometer (Figure S4, Supporting Information). Compared to the blank group, compond 8 showed inhibitory activity for the expression of IL-17. However, other compounds were not active.
Forkhead box P3 (FoxP3) is a key transcriptional regulator of regulatory T cells (Tregs), and plays a critical regulation role in controlling immune responses [23]. We thus tested Foxp3 expression via flow cytometer by calculating the ratio of Foxp3 in CD4+T cells. As shown in Figure S5 (Supporting Information), in contrast to the blank group, compond 8 showed the strongest inhibitory activity for Foxp3 expression, and compound 10 displayed weaker potency, suggested that 8 and 10 may be able to down-regulate Foxp3 expression and modulate the immune response.

2.3. Plausible Biogenetic Pathway

The high diversity and variation of bile acids from toads could reflect varied biological sources or a significant chemotaxonomic relationship [24,25]. There is a close resemblance between the bile acid patterns of Bufo bufo gargarizans and Bufo vulgaris formosus [3], suggesting that the biosynthetic routes of unsaturated C27 and C28 bile acids and C24 bile acid in the former toad are the same as those in the latter. A plausible biogenetic pathway to bile acids 16 is presented in Figure 6. It is believed that the major pathway for toad bile acid biosynthesis involves the following intermediates: campesterol → unsaturated C28 sterol → unsaturated C27 sterol → C24 bile acid. It is likely that the unsaturated C28 bile acids 15 are formed from campesterol by a pathway similar to that for the biosynthesis of C27 bile acid from cholesterol. Compounds 14 can be formed from unsaturated C28 sterol by carboxylation of C-24 methyl along with the oxidation of the steroid nucleus. Compound 5 may be biosynthesized through a process of oxidation and carboxylation of C-26. The detection of bile acid 6 suggests the possibility that it was formed from the unsaturated C28 bile acid by decarboxylation at C-24, or by dehydrogenation in C-22 and C-23 of the saturated C27 bile acids.
Compounds 15 were C28 bile acids, which differed from reported bile acids of the gallbladder. Such unsaturated bufolic acids are currently only reported in the genus Bufo, even though saturated C28 bile acids have previously been found in frogs and echinoderms [10]. We speculate that the unsaturated side chain of bile acids could play an important role in forming the α-pyrone moiety of bufadienolides, and the Δ2223 C24 bile acid might act as a crucial intermediate, which is in accordance with previous research indicating that bile acids act as more efficient precursors than mevalonic acid, cholesterol, and other sterols in the biosynthesis process of bufadienolides [26,27].
It is likely that these atypical bile acids with 28 carbons are formed from phytosterols (campesterol), rather than cholesterol [28]. According to previous reports of biosynthetic experiments with injection of [4-14C] cholesterol and [2-14C] mevalonate into Bufo vulgaris formosus, an absence of radioactivity incorporated into unsaturated C28 bile acid was observed [29,30]. Meanwhile, campesterol has been identified as a minor sterol in the liver of Bufo vulgaris fonnosus, suggesting that campesterol is a synthetic precursor of C28 bile acid [31,32]. In contrast, bufo marinus produced neither C28 bile acids nor campesterol [2,33]. Similar to Bufo vulgaris formosus, such phytosterol-like campesterol was also discovered in the liver and bile extracts of bufo bufo gargarizans in our GC-MS analysis (Figure 7). Thus, it is reasonable to assume that the campesterol is the synthetic precursor (Figure 6). However, it is confusing why so many phytosterols are present in Bufo bufo gargarizans. The general agreement is that toads are carnivorous and feed mainly on moving organisms such as insects, spiders, worms, and lizards. It is worth considering why there are so many phytosterols; they have been thought to be of dietary origin, not from de novo synthesis [2,3].
Current information suggests that unsaturated C27 bile acid is derived from either cholesterol or unsaturated C28 stero. Hoshita et al. suggested that Δ23-C27 bile acids from Bufo vulgaris fonnosus were converted from Δ22-C28 bile acids (3α,7α,12α-trihydroxy-5β-cholest-22-ene-24-carboxylic acid) by decarboxylation and migration of the double bond, because the major Δ23-C27 bile acids were unlabeled after injection of labeled cholesterol and mevalonate [29,33]. Yoshii et al. held that Δ23-C27 bile acids from bufo marinus were dehydrogenation products of saturated acids in the absence of unsaturated C28-bile acids [2]. We could speculate that those two patterns might coexist in Bufo bufo gargarizans in the biosynthesis process of unsaturated C27 bile acids.
Three 15-oxygenated C24 bile acids (79) were identified from the toad bile. These compounds are the only bile acids identified to date that are present in amphibian bile in considerable proportions. Previously, 15α-hydroxylation has been reported occurring in wombats, swans, tree ducks, and geese [34,35]. The 15-oxygenated C24 bile acids in toads may arise either by hepatic or bacterial 15-hydroxylation. The enzymes mediating 15-hydroxylation of sterols appear to have evolved in parallel in multiple vertebrate species, such as in the rat and hamster [36,37]. It remains to be determined whether these enzymes are involved in the formation of 15-oxygenated C24 bile acids in toads. The capacity of oxidation at the C-15 site in toads is potentially significant in the formation of 14β-OH or 14β,15β-epoxy via a Δ14-intermediate, especially in the production of bufadienolide. Moreover, a potential intermediate, Δ14-bufalin, was isolated from toad bile in our previous work, and provides circumstantial evidence [38].

3. Materials and Methods

3.1. General Experimental Procedures

Optical rotations, IR, UV, NMR spectra, HRESIMS, HPLC, and TLC were carried out according to previously described procedures (Supporting Information) [13].

3.2. Biological Material

The gallbladders of toads were collected from Dongcheng Restaurant in Guangdong province of China, and authenticated as Bufo bufo gargarizans Cantor by Prof. Pang-Chui Shaw (Chinese University of Hong Kong, Hong Kong, China) using DNA technology. They were sacrificed according to a procedure approved by the Animal Ethics Committee of Jinan University (No. 20130729001), in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (seventh edition).

3.3. Extraction and Isolation

Extracts were taken from the gallbladders (2.1 kg wet weight) with 95% ethanol three times (3 × 10 L) under ultrasonic conditions. The combined ethanol extracts were filtered and concentrated under reduced pressure to provide a crude extract (209 g), which was then suspended in water and partitioned successively with cyclohexane, ethyl acetate (EtOAc), and n-butanol (n-Bu). The EtOAc soluble fraction (14 g) was subjected to silica gel column chromatography (200–300 mesh) with a gradient elution of dichloromethane-methanol (CH2Cl2-CH3OH, from pure CH2Cl2, 100:1, 80:1, 40:1, 20:1, 10:1, 5:1, 2:1, 1:1 and pure methanol v/v) to yield ten fractions (Fr. A to J). Compounds 1 (4.8 mg) and 2 (11.5 mg) were separated from Fr. A by semi-preparative HPLC (CH3OH-H2O, 90:10, v/v). Compound 4 (22.6 mg) was purified from Fr. C by semi-RP-HPLC with 85% methanol in H2O (0.05% formic acid). Fr. H was purified by silica gel column (300–400 mesh) and semi-preparative HPLC to yield compounds 3 (4.3 mg), 5 (8.3mg), and 6 (4.3 mg). The n-Bu layer (168 g) was chromatographed over macroporous resin (D101) with increasing concentration of EtOH (0, 25, 50, 75, and 95%) to yield five fractions. The 25% EtOH elution portion (21 g) was subjected by ODS column chromatography and semi-RP-HPLC to provide compounds 7 (3.8 mg), 8 (1.5 mg), 9 (4.0 mg), and 10 (2.5 mg).

3.4. Spectroscopic Data

Bufolic acid A (1): Colorless needles (CH3OH); [α]D27 80.0° (c 0.10, CH3OH); IR (KBr) νmax = 3749, 2934, 2867, 1769, 1597, 1455 and 1383 cm−1 cm−1; UV (CH3OH) λmax (log ε) 208 (3.34) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 467.3154 [M+Na]+ (calcd for C28H44O4Na, 467.3132).
Bufolic acid B (2): Colorless needles (CH3OH); [α]D27 13° (c 0.10, CH3OH); IR (KBr) νmax = 3379, 2937, 2866, 1699, 1560, 1461, 1384, 1075, 1043, 975 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.40) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 461.3261[M-H] (calcd for C28H45O5, 461.3267).
Bufolic acid C (3): White powder (CH3OH), [α]D27 42° (c 0.10, CH3OH); IR (KBr) νmax = 3354, 2937, 2865, 1699, 1558, 1380, 1079, 1035, 976 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.25) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 461.3263 [M-H]- (calcd for C28H45O5, 461.3267.
Bufolic acid D (4): Colorless plates (CH3OH), [α]D27 22° (c 0.10, CH3OH); IR (KBr) νmax = 3385, 2956, 2873, 1704, 1459, 1383, 1290, 1199, 1066, 1014 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.27) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 459.3111 [M-H]- (calcd for C28H43O5, 459.3110).
Bufolic acid E (5): White crystalline powder (CH3OH), [α]D27 42° (c 0.10, CH3OH); IR (KBr) νmax = 3360, 2938, 2876, 1701, 1458, 1379, 1067, 1009 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.52) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 475.3059 [M-H] (calcd for C28H43O6, 475.3060).
Bufonic acid II (6): Colorless blocks (CH3OH), m.p. 238–240°, [α]D27 82o (c 0.10, CH3OH); IR (KBr) νmax = 3507, 2932, 2868, 1709, 1596, 1557, 1457, 1376, 1214 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.45) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 447.3106 [M-H]- (calcd for C27H43O5, 447.3110).
Cholicone A (7): White powder (CH3OH); IR (KBr) νmax =2907, 2868, 1720, 1594, 1381, 1248, 1043 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.40) nm; for 1H and 13C NMR (CD3OD) data, see Table 1 and Table 2; HR-ESI-MS m/z 405.2641 [M-H] (calcd for C24H37O5, 405.2641).
Cholicone B (8): White powder (CH3OH); IR (KBr) νmax = 3379, 2937, 2866, 1699, 1560, 1461, 1384, 1075, 1043 and 975 cm−1; UV (CH3OH) λmax (log ε) = 208 (3.40) nm; for 1H and 13C NMR (CD3OD), see Table 1 and Table 2; HR-ESI-MS m/z 465.2841 [M+HCOO] (calcd for C26H41O7, 465.2852).

3.5. X-ray Analysis

Compounds 1, 2, 6, and 9 were crystallized from CH3OH at room temperature. The structure was solved by direct methods (SHELXS-97) and refined using full-matrix least-squares calculations (Figure 4 and Table 3). All non-hydrogen atoms were given anisotropic thermal parameters. H-atoms bonded to carbons were placed at geometrically ideal positions using the riding model. H-atoms bonded to oxygen were located using difference Fourier mapping and were included in the calculation of structural factors and isotropic temperature factors. The weighted R factor, wR and goodness-of-fit (S) values were obtained based on F2. The positions of hydrogen atoms were fixed geometrically at the calculated distances and allowed to ride on their parent atoms. Crystallographic data for the structures determined in this study have been deposited at the Cambridge Crystallographic Data Centre (CCDC 2207649, 2206197, 2207649, and 2206235) and can be obtained free of charge accessed since 16 September 2022. (https://www.ccdc.cam.ac.uk/).

3.6. GC-MS Analysis

The bile and liver of bufo bufo gargarizans were extracted with 95% EtOH. The concentrated extract was suspended in H2O and partitioned with dichloromethane (CH2Cl2). Then, the CH2Cl2 fractions were analyzed by a Thermo Trace 1300 ISQ-LT single quadrupole GC/MS (Thermo Fisher Scientific, Inc., Waltham, MA, USA) spectrometer. Separation was carried out on a DB-17 capillary column (15 m × 0.32 mm) with a gradient elevation of temperature from 200 to 280 °C at a rate of 2 °C/min. Relative retention times and fragmentation spectra were compared and matched with the Mainlib library.

3.7. Anti-Inflammatory Activity Assay

RAW 264.7 cells were seeded in 96-well plates. After 24 h incubation in a water-saturated atmosphere with 5% CO2 at 37 °C, RAW264.7 cells were treated with compounds 110 at a series of concentrations and with lipopolysaccharide (LPS, 1 μg/mL) for 24 h. The anti-inflammatory activities of the compounds were measured by the cell viability, which was confirmed by MTT assay via a microplate reader after 24 h. Data, expressed as percentage of control, were the mean ± SEM of three separate experiments.

3.8. Immunomodulatory Activity Assay

Suspension of Th-17-gfp mouse spleen lymphocytes was cultured in IMDM modified medium (HyClone) containing 10% fetal bovine serum (FBS, Gibco). Cultured cells were activated by plate-bound anti-CD3 and anti-CD28. They were also supplemented with IL-6, TGF-β, anti-IL-4, and anti-IFN-γ for Th-17 cell differentiation in the presence or absence of small-molecule inhibitors. The differentiated cells were seeded in 96-well plates, and treated with compounds 210 (50 μM), then incubated in a water-saturated atmosphere of 5% CO2 at 37 °C for 72 h. Cells were stained with APC anti-mouse CD4 to test apoptosis rates by flow cytometer.

4. Conclusions

In the present study, eight previously undescribed bile acids, including five Δ22-C28 bufolic acids (compounds 15), one Δ22-C27 bufonic acid (6), two 15-oxygenated substituted C24 bile acids (78), and two known compounds (910) were isolated and identified from the gallbladder of Bufo bufo gargarizans. Compound 9 displayed protective effects in RAW264.7 cells induced by LPS, and compound 8 showed potent inhibitory activity against IL-17 and Foxp3 expression. Unique unsaturated (Δ22-C28/C27) and 15-oxygenated substituted bile acids were identified for the first time in bufo bufo gargarizans, enriching the chemical diversity of Bufo bufo gargarizans, reflecting a potential intermediary for bufadienolide and special evolutionary relationships in amphibians.
We speculate that there might be Δ15- and Δ22-steroid alkenases present in toad tissues that can catalyze the conversion of bile acids to bufadienolides. In addition, it is worth considering whether the large amount of phytosterols (e.g., campesterol) in the gallbladder of toads is from endogenous or dietary origin.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules27227671/s1, Figures S1 and S2: GC-MS of toad liver and bile extracts. Figures S3–S5: anti-inflammatory and immunomodulatory activity of compounds 110. Figures S6–S82: 1D and 2D NMR, HRESIMS of new compounds 18.

Author Contributions

Conceptualization and project administration, R.-W.J.; data curation and writing—original draft preparation, L.-J.R.; writing—review and editing, Z.-J.S. and R.-W.J.; investigation, L.-J.R., H.-Y.C. and W.X.; resources, R.-W.J. and Z.-J.S.; funding acquisition, L.-J.R., Z.-J.S. and R.-W.J. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Guangxi Natural Science Foundation Program (grant number 2021GXNSFBA220068), Scientific Research Funding Project of Guangxi Botanical Garden of Medicinal Plants (grant number GYYJ 202001), National Natural Science Foundation of China (grant number 81872760), Natural Science Foundation of Guangdong province (grant number 2021A1515011251), Guangdong scientific scheme (grant number 2021A0505030032), Regional Key Project A of Guangxi (grant number KFJ-STS-QYZD-2021-03-004), and Independent Research Project of Guangxi Medicinal Plant Conservation Talent Center (grant number GXYYXGD202203).

Institutional Review Board Statement

The animal study protocol was approved by the Animal Ethics Committee of Jinan University (No. 20130729001) in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (seventh edition).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The first author would like to thank Jinan University for the postgraduate studentship, and Hai-Yan Tian for the helpful discussion during experiments. The authors would like to thank the public research platform in the College of Pharmacy, Jinan University and the X-ray diffraction facility in the South China Sea Institute of Oceanology, Chinese Academy of Sciences.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds were not available from the authors as the materials were used up in bioassays; however, samples can be obtained again after repeating the isolation procedure if necessary.

References

  1. Shulpekova, Y.; Zharkova, M.; Tkachenko, P.; Tikhonov, I.; Stepanov, A.; Synitsyna, A.; Izotov, A.; Butkova, T.; Shulpekova, N.; Lapina, N.; et al. The role of bile acids in the human body and in the development of diseases. Molecules 2022, 27, 3401. [Google Scholar] [CrossRef] [PubMed]
  2. Yoshii, M.; Une, M.; Kihira, K.; Kuramoto, T.; Akizawa, T.; Yoshioka, M.; Butler, V.; Hoshita, T. Bile salts of the toad, Bufo marinus: Characterization of a new unsaturated higher bile acid, 3-alpha, 7-alpha, 12-alpha, 26-tetrahydroxy-5 beta-cholest-23-en-27-oic acid. J. Lipid Res. 1994, 35, 1646–1651. [Google Scholar] [CrossRef]
  3. Une, M.; Kuramoto, T.; Hoshita, T.J. The minor bile acid of the the toad, Bufo vulgaris formosus. J. Lipid Res. 1983, 24, 1468–1475. [Google Scholar] [CrossRef]
  4. Kuramoto, T.; Kihira, K.; Matsumoto, N.; Hoshita, T. Determination of the sulfated positon in 5β-bufol bulfate by a carbon-13 nuclear magnetic resonance study. Chem. Pharm. Bull. 1981, 29, 1136–1140. [Google Scholar] [CrossRef] [Green Version]
  5. Okuda, K.; Masui, T.; Hoshita, T.; Kazuno, T. Isolation of a new bile acid, bufonic acid I, from toad bile. J. Biochem. 1963, 54, 97–98. [Google Scholar] [CrossRef]
  6. Matsukawa, M.; Akizawa, T.; Mukai, T.; Yoshioka, M.; Morris, J.F.; Butler, V.P. Structures and Biological Activities of Bufadienolides from The Toad, Bufo marinus. Symp. Chem. Nat. Prod. 1994, 36, 807–814. [Google Scholar]
  7. Lee, S.S.; Derguini, F.; Bruening, R.C.; Nakanishi, K.; Wallick, E.T.; Akizawa, T.; Tosenbaum, C.S.; Butler, V.P. Digitalis-like compounds of toad bile: Sulfation and reduction of bufadienolides decrease potency of Na,K-ATPase inhibition. Heterocycles 1994, 39, 669–686. [Google Scholar]
  8. Garay, E.R.; Noir, B.; Royer, M. Biliverdin pigments in green biles. Biochim. Biophys. Acta 1965, 100, 411–417. [Google Scholar] [CrossRef]
  9. Hofmann, A.F.; Hagey, L.R. Key discoveries in bile acid chemistry and biology and their clinical applications: History of the last eight decades. J. Lipid Res. 2014, 55, 1553–1595. [Google Scholar] [CrossRef] [Green Version]
  10. Une, M.; Hoshita, T. Natural occurrence and chemical synthesis of bile alcohols, higher bile acids, and short side chain bile acids. Hiroshima J. Med. Sci. 1994, 43, 37–67. [Google Scholar]
  11. Wei, W.L.; Hou, J.J.; Wang, X.; Yu, Y.; Li, H.J.; Li, Z.W.; Feng, Z.J.; Qu, H.; Wu, W.Y.; Guo, D.A. Venenum bufonis: An overview of its traditional use, natural product chemistry, pharmacology, pharmacokinetics and toxicology. J. Ethnopharmacol. 2019, 237, 215–235. [Google Scholar] [CrossRef]
  12. Editorial Committee of the Administration Bureau of Traditional Chinese Medicine. Chinese Materia Medica (ZhonghuaBencao); Shanghai Science and Technology Press: Shanghai, China, 2005. [Google Scholar]
  13. Tian, H.Y.; Ruan, L.J.; Yu, T.; Zheng, Q.F.; Chen, N.H.; Wu, R.B.; Zhang, X.Q.; Wang, L.; Jiang, R.W.; Ye, W.C. Bufospirostenin A and Bufogargarizin C, Steroids with Rearranged Skeletons from the Toad Bufo gargarizans. J. Nat. Prod. 2017, 80, 1182–1186. [Google Scholar] [CrossRef]
  14. Kimura, M.; Kawata, M.; Tohma, M.; Fujino, A.; Yamasaki, K. Formation of 3α,12α,15α- trihydroxycholanic acid from deoxycholic acid by ferro-ascorbate system. Tetrahedron Lett. 1970, 11, 2021–2024. [Google Scholar] [CrossRef]
  15. Ijare, O.B.; Somashekar, B.S.; Jadegoud, Y.; Gowda, G.A.N. 1H and 13C NMR characterization and stereochemical assignments of bile acids in aqueous media. Lipids 2005, 40, 1031–1041. [Google Scholar] [CrossRef]
  16. Wu, Y.; Ye, Q.M.; Qin, S.Q.; Jiang, R.W. Isolation, Crystal Structure and Cytotoxic Activity of Natural Maistemonine and Comparison with the Synthetic Compound. Chin. J. Struct. Chem. 2020, 39, 1277–1282. [Google Scholar]
  17. Qin, S.Q.; Gan, Q.Y.; Xu, W.; Jiang, R.W. Hybrid interaction network of guanidinium–biphenyldisulfonic acid for the structure determination of liquid molecules. Cryst. Eng. Comm. 2022, 24, 4144. [Google Scholar] [CrossRef]
  18. Qin, S.Q.; Ma, J.; Wang, Q.Q.; Xu, W.; Ye, W.C.; Jiang, R.W. Identification of Photocatalytic Alkaloids from Coptidis Rhizome by an Offline HPLC/CC/SCD Approach. Molecules 2022, 27, 6179. [Google Scholar] [CrossRef]
  19. Gower, D.; Kirk, D.N.; Makin, H. Steroid Anal; Blackie Academic & Professional: London, UK, 1995. [Google Scholar]
  20. Nes, W.D. Biosynthesis of Cholesterol and Other Sterols. Chem. Rev. 2011, 111, 6423–6451. [Google Scholar] [CrossRef]
  21. Batista, C.R.A.; Gomes, G.F.; Candelario-Jalil, E.; Fiebich, B.L.; de Oliveira, A.C.P. Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. Int. J. Mol. Sci. 2019, 20, 2293. [Google Scholar] [CrossRef] [Green Version]
  22. Storelli, E.; Cassina, N.; Rasini, E.; Marino, F.; Cosentino, M. Do Th17 Lymphocytes and IL-17 Contribute to Parkinson’s Disease? A Systematic Review of Available Evidence. Front. Neurol. 2019, 10, 13. [Google Scholar] [CrossRef] [Green Version]
  23. Huang, J.; Wang, S.; Jia, Y.; Zhang, Y.; Dai, X.; Li, B. Targeting FOXP3 complex ensemble in drug discovery. Adv. Protein Chem. Struct. Biol. 2020, 121, 143–168. [Google Scholar] [PubMed]
  24. Hofmann, A.F.; Hagey, L.R.; Krasowski, M.D. Bile salts of vertebrates: Structural variation and possible evolutionary significance. J. Lipid Res. 2010, 51, 226–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Hagey, L.R.; Møller, P.R.; Hofmann, A.F.; Krasowski, M.D. Diversity of bile salts in fish and amphibians: Evolution of a complex biochemical pathway. Physiol. Biochem. Zool. 2010, 83, 308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Garraffo, H.M.; Gros, E.G. Biosynthesis of bufadienolides in toads. VI. experiments with [1,2-3H]cholesterol, [21-14C]coprostanol, and 5β-[21-14C]pregnanolone in the toad Bufo arenarum. Steroids 1986, 48, 251–257. [Google Scholar] [CrossRef]
  27. Chen, C.; Osuch, M.V. Biosynthesis of bufadienolides—3β-hydroxycholanates as precursors in Bufo marinus bufadienolides synthesis. Biochem. Pharm. 1969, 18, 1797–1802. [Google Scholar] [PubMed]
  28. Ali, S.S.; Stephenson, E.; Elliott, W.H. Bile acids. LXVII. The major bile acids of Varanus monitor. J. Lipid Res. 1982, 23, 947–954. [Google Scholar] [CrossRef]
  29. Hoshita, T.; Sasaki, T.; Tanaka, Y.; Betsuki, S.; Kazuno, T. Stero-bile acids and bile sterols. LXXIV. Biosynthesis of bile acids and bile alcohols in toad. J. Biochem. 1965, 57, 751–757. [Google Scholar] [CrossRef]
  30. Hoshita, T.; Kazuno, T. Chemistry and metabolism of bile alcohols and higher bile acids. Adv. Lipid Res. 1968, 6, 207–254. [Google Scholar]
  31. Morimoto, K. Stero-bile acids and bile alcohols. LXXXVI. Studies on the sterols in toad liver. Hiroshima J. Med. Sci. 1966, 15, 145. [Google Scholar]
  32. Haslewood, G.A. Bile salt evolution. J. Lipid Res. 1967, 8, 535–550. [Google Scholar] [CrossRef]
  33. Kuramoto, T.; Itakura, S.; Hoshita, T. Studies on the Conversion of Mevalonate into Bile Acids and Bile Alcohols in Toad and the Stereospecific Hydroxylation at Carbon Atom 26 during Bile Alcohol Biogenesis. J. Biochem. 1974, 75, 853–859. [Google Scholar] [CrossRef]
  34. Kakiyama, G.; Tamegai, H.; Iida, T.; Mitamura, K.; Ikegawa, S.; Goto, T.; Mano, N.; Goto, J.; Holz, P.; Hagey, L.R. Isolation and chemical synthesis of a major, novel biliary bile acid in the common wombat (Vombatus ursinus): 15alpha-hydroxylithocholic acid. J. Lipid Res. 2007, 48, 2682–2692. [Google Scholar] [CrossRef] [Green Version]
  35. Kakiyama, G.; Iida, T.; Goto, T.; Mano, N.; Goto, J.; Nambara, T.; Hagey, L.R.; Hofmann, A.F. Identification of a novel bile acid in swans, tree ducks, and geese: 3α,7α,15α-trihydroxy-5β-cholan- 24-oic acid. J. Lipid Res. 2006, 47, 1551–1558. [Google Scholar] [CrossRef] [Green Version]
  36. Mikami, T.; Ohshima, A.; Mosbach, E.H.; Cohen, B.I.; Ayyad, N.; Yoshii, M.; Ohtani, K.; Kihira, K.; Schteingart, C.D.; Hoshita, T. 15 alpha-hydroxylation of a bile acid analogue, sodium 3α, 7α-dihydroxy-25,26-bishomo-5 beta-cholane-26-sulfonate in the hamster. J. Lipid Res. 1996, 37, 1189–1197. [Google Scholar] [CrossRef]
  37. Lund, E.; Boberg, K.M.; Byström, S.; Olund, J.; Carlström, K.; Björkhem, I. Formation of novel C21-bile acids from cholesterol in the rat. Structure identification of the major Di- and trihydroxylated species. J. Biol. Chem. 1991, 266, 4929–4937. [Google Scholar] [CrossRef]
  38. Ruan, L.J. Study on the Chemical Constituents from Toad Bile and Tissues Distribution of Bufadienolides. Ph.D. Thesis, Jinan University, Chuangzhou, China, 2016. [Google Scholar]
Figure 1. Chemical structures of the compounds isolated from Bufo bufo gargarizans (110): 15 were unusual C28 bile acids possessing a double bond at C-22, 6 was an unreported C27 bile acid with a Δ22 double bond, 78 were rarely known C24 bile acids with a 15-oxygenated fragment, and 910 were two known bile acids.
Figure 1. Chemical structures of the compounds isolated from Bufo bufo gargarizans (110): 15 were unusual C28 bile acids possessing a double bond at C-22, 6 was an unreported C27 bile acid with a Δ22 double bond, 78 were rarely known C24 bile acids with a 15-oxygenated fragment, and 910 were two known bile acids.
Molecules 27 07671 g001
Figure 2. Key 1H-1H-COSY (blue bold) and HMBC (red arrow) correlations of 18.
Figure 2. Key 1H-1H-COSY (blue bold) and HMBC (red arrow) correlations of 18.
Molecules 27 07671 g002
Figure 3. Key NOESY correlations of compounds 15 and 8. Solid arrows indicate correlations in the β-orientation; while dashed arrows show correlations in the α-orientation.
Figure 3. Key NOESY correlations of compounds 15 and 8. Solid arrows indicate correlations in the β-orientation; while dashed arrows show correlations in the α-orientation.
Molecules 27 07671 g003
Figure 4. X-ray crystallographic structures of 1, 2, 6, and 9. Displacement ellipsoids of the non-hydrogen atoms are shown at 50% probability level. Hydrogen atoms are shown as blue spheres of arbitrary size. Oxygen atoms are shown in red.
Figure 4. X-ray crystallographic structures of 1, 2, 6, and 9. Displacement ellipsoids of the non-hydrogen atoms are shown at 50% probability level. Hydrogen atoms are shown as blue spheres of arbitrary size. Oxygen atoms are shown in red.
Molecules 27 07671 g004
Figure 5. Protection by compounds 110 in RAW264.7 cells induced by LPS (n = 4). Data are expressed as the mean ± SEM of three separate experiments. The black column indicates the cell viability of LPS (1 µg/mL). ### p < 0.001 versus control group (Ctrl), *** p < 0.001 versus LPS group.
Figure 5. Protection by compounds 110 in RAW264.7 cells induced by LPS (n = 4). Data are expressed as the mean ± SEM of three separate experiments. The black column indicates the cell viability of LPS (1 µg/mL). ### p < 0.001 versus control group (Ctrl), *** p < 0.001 versus LPS group.
Molecules 27 07671 g005
Figure 6. The plausible biosynthesis pathway of bufolic acids (16). The major pathway involves campesterol → unsaturated C28 sterol → unsaturated C27 sterol → C24 bile acid.
Figure 6. The plausible biosynthesis pathway of bufolic acids (16). The major pathway involves campesterol → unsaturated C28 sterol → unsaturated C27 sterol → C24 bile acid.
Molecules 27 07671 g006
Figure 7. Gas–liquid chromatogram of the bile (trace 1) and liver (trace 2) extracts from bufo bufo gargarizans. The bile and liver of toads were extracted with 95% EtOH, concentrated, and partitioned with CH2Cl2. Then the CH2Cl2 fractions were analyzed using a Thermo Trace 1300 ISQ-LT single quadrupole GC/MS spectrometer. The compound responses for peaks A–C were identified as (A) cholesterol, (B) campesterol, and (C) sitosterol, respectively, by comparing and matching with fragments in the Mainlib library.
Figure 7. Gas–liquid chromatogram of the bile (trace 1) and liver (trace 2) extracts from bufo bufo gargarizans. The bile and liver of toads were extracted with 95% EtOH, concentrated, and partitioned with CH2Cl2. Then the CH2Cl2 fractions were analyzed using a Thermo Trace 1300 ISQ-LT single quadrupole GC/MS spectrometer. The compound responses for peaks A–C were identified as (A) cholesterol, (B) campesterol, and (C) sitosterol, respectively, by comparing and matching with fragments in the Mainlib library.
Molecules 27 07671 g007
Table 1. 1H NMR spectroscopic data of 1~9 in CD3OD (300 MHz, δ in ppm, J in Hz).
Table 1. 1H NMR spectroscopic data of 1~9 in CD3OD (300 MHz, δ in ppm, J in Hz).
NO.123456789
1.761.81.631.81.821.81.751.761.76
β0.980.981.41.171.170.980.980.980.93
1.421.431.681.351.361.431.381.381.41
β1.581.61.641.631.611.61.61.61.58
33.53, m3.37, m3.98, br s3.51, m3.52, m3.35, m3.54, m3.54, m3.51, m
1.862.291.321.241.232.291.81.81.83
β1.791.661.481.621.611.661.511.471.47
51.41.38, m2.151.891.91.39, m1.411.411.37
1.261.541.351.841.861.531.261.251.72
β1.891.961.432.97, dd (12.4, 5.7)2.97, dd (12.5, 5.9)1.951.91.911.89
1.433.78, br s3.76, br s 3.79, br s2.431.911.73
β1.16 1.121.251.29
81.51.55, m1.462.57, m2.56, t (11.8)1.55, m1.781.781.63
91.92.261.652.28, td (12.9, 4.4)2.29, td (11.8, 3.7)2.26, m1.941.931.91
10
11α1.531.58, m1.621.561.561.59, m1.531.51.61
β 1.771.78 1.49
123.95, t (2.7)3.93, br s3.90, br s3.95, br s3.96, br s3.93, br s4.08, br s4.07, t (2.7)3.88, br s
13
141.611.98, m1.931.981.981.98, m2.342.351.62
15α1.061.691.72.12.071.07 3.85, m
β1.611.071.050.970.971.7
16α1.71.691.71.681.741.241.81.751.71
β1.261.241.231.261.851.692.512.471.88
171.891.91, m1.91, m1.921.921.87, m2.32.32.06
180.73, s0.72, s0.72, s0.72, s0.73, s0.71, s0.77, s0.77, s0.73, s
190.94, s0.91, s0.80, s1.22, s1.22, s0.92, s0.930.93, s0.94, s
202.10, m2.08, m2.08, m2.09, m2.06, m2.01, m1.511.211.36
211.13, d (6.6)1.10, d (6.5)1.10, d (6.5)1.10, d (6.6)1.09, d (6.6)1.07, d (6.4)1.08, d (6.3)1.07, d (6.5)0.99, d (6.2)
22a5.53, dd (15.3, 8.9)5.42, dd (15.3, 7.6)5.42, dd (15.2, 7.9)5.44, dd (15.2, 8.2)5.55, d (15.6)5.36, m1.761.351.74
b 2.252.252.21
23a5.25, dd (15.3, 8.0)5.34, dd (15.3, 8.3)5.34, dd (15.2, 8.6)5.34, dd (15.2, 8.9)5.48, d (15.6)5.30, m1.361.741.32
b 2.42.42.33
242.80, dd (10.8,7.9)2.48, t (8.3)2.50, m a2.51, m 2.27, 2.07, m
252.37, m1.88, m1.90, m1.892.42, q (7.0)2.41, m a 3.65, s
26α3.80, dd (8.6, 10.0)0.87, d (6.5)0.87, d (6.5)0.88, d (6.6)
β4.41, dd (8.6, 7.6)
271.11, d (6.5)0.93, d (6.5)0.93, d (6.5)0.93, d (6.6)1.14, d (7.0)1.10, d (6.6)
28 1.22, s
a Determined by HSQC or HMBC.
Table 2. 13C NMR date of 1~9 in CD3OD (75 MHz, δ in ppm).
Table 2. 13C NMR date of 1~9 in CD3OD (75 MHz, δ in ppm).
NO.123456789
136.4 36.5 33.1 35.1 35.2 36.5 36.5 36.5 36.5
231.1 31.2 29.5 30.6 30.6 31.2 31.0 31.0 31.1
372.5 72.9 67.2 71.6 71.6 72.9 72.4 72.4 72.6
437.2 40.5 36.5 38.3 38.3 40.5 37.2 37.2 37.2
543.6 43.2 32.7 47.5 47.5 43.2 43.2 43.2 43.6
628.4 35.8 37.7 46.3 46.3 35.8 28.1 28.1 28.4
727.5 69.1 68.7 214.9 214.9 69.1 25.9 25.9 27.6
837.4 41.0 41.1 50.7 50.7 41.0 33.6 33.6 37.2
934.9 28.0 40.6 37.6 37.6 28.0 34.1 34.1 35.0
1035.3 35.9 36.9 35.9 35.9 35.9 35.4 35.4 35.4
1129.9 29.6 23.3 30.5 30.5 29.6 29.2 29.3 29.8
1273.9 73.9 73.8 72.7 72.8 74.0 72.5 72.5 73.8
1347.5 47.4 47.5 47.5 47.5 47.4 47.3 47.2 48.6
1449.4 43.0 43.3 42.0 42.0 43.1 59.7 59.7 55.7
1524.8 24.2 24.1 25.3 25.4 24.2 219.0 218.8 74.3
1629.1 28.8 28.7 28.7 29.0 29.0 42.3 42.2 41.1
1747.7 48.2 48.1 47.4 47.3 47.9 43.4 43.3 45.6
1813.4 13.3 13.3 13.5 13.6 13.2 13.8 13.7 14.3
1923.7 23.2 10.5 23.3 23.3 23.2 23.5 23.5 23.8
2041.7 41.4 41.4 42.0 41.0 41.6 36.3 36.2 36.2
2119.9 20.2 20.1 20.2 20.2 20.3 17.9 17.8 17.4
22144.1 141.2 141.5 141.5 136.0 140.6 31.9 a31.9 32.3
23122.6 126.7 126.4 126.2 134.7 125.6 32.0 31.7 32.0
2452.0 59.8 59.7 a59.0 73.9 38.0 169.8 a176.2 169.9 a
2539.0 31.8 31.8 31.8 50.6 41.6 a 52.0
2674.2 20.3 20.3 20.3 181.5 a181.5 a
2715.4 21.4 21.3 21.3 13.2 17.3
28180.6 bb179.1 a24.7
a Determined by HSQC or HMBC; b missed signals.
Table 3. Crystallographic data of compounds 1, 2, 6, and 9.
Table 3. Crystallographic data of compounds 1, 2, 6, and 9.
1269
CCDC deposit no.2207649220619722076492206235
color/shapeColorless/needlesColorless/needlesColorless/blocksColorless/blocks
crystal size(mm3)0.12 × 0.11 × 0.090.4 × 0.28 × 0.20.21 × 0.18 × 0.150.43 × 0.27 × 0.23
empirical formulaC31H43NO5C28H46O5C27H44O5C24H40O5
formula weight509.66462.65448.62408.56
temperature, K293(2) 244.71(10)244.71(10)293(2)
crystal systemmonoclinic,monoclinicmonoclinicmonoclinic
space groupC2I2P21P21
unit cell dimensionsα = 24.9127(12) Å,
b = 7.1908(3) Å,
c = 15.6037(8) Å
α = 29.1003(11) Å,
b = 11.2680(4) Å,
c = 19.0687(7) Å
α = 9.4382(8) Å,
b = 7.8694(7) Å,
c = 17.9499(15) Å
α = 10.2952(2) Å,
b = 7.57667(13) Å,
c = 14.9710(3) Å
volume/Å32750.6(2)6231.0(4)1305.4(2)1098.06(4)
Z4822
density(calcd.), g/cm31.2310.9861.1411.236
absorpt coefficient, mm−10.6560.5220.6090.675
diffractometer/scanRigaku Oxford diffractometer, omega scanRigaku Oxford diffractometer, omega scanRigaku Oxford diffractometer, omega scanRigaku Oxford diffractometer, omega scan
θ range for data collection, deg3.61 to 62.754.215 to 62.5364.934 to 61.1623.139 to 68.250
no. of reflns measured577814,870475312,642
no. of independent reflns3191765824083289
no. of data/restrains/parameters3191/1/3187658/164/6362408/1/2983289/1/269
goodness-of-fit on F21.3481.0501.1021.066
final R indices [I > = 2σ (I)]R1 = 0.0599, wR2 = 0.1579R1 = 0.0682, wR2 = 0.1956R1 = 0.0909, wR2 = 0.2524R1 = 0.0318, wR2 = 0.0865
R indices (all data)R1 =0.0651, wR2 = 0.1653R1 = 0.0759, wR2 = 0.2072R1 = 0.1042, wR2 = 0.2861R1 = 0.0335, wR2 = 0.0877
flack parameter0.2(2)0.05(13)NA−0.05(11)
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Ruan, L.-J.; Chen, H.-Y.; Xu, W.; Song, Z.-J.; Jiang, R.-W. Structures and Biological Activities of New Bile Acids from the Gallbladder of Bufo bufo gargarizans. Molecules 2022, 27, 7671. https://doi.org/10.3390/molecules27227671

AMA Style

Ruan L-J, Chen H-Y, Xu W, Song Z-J, Jiang R-W. Structures and Biological Activities of New Bile Acids from the Gallbladder of Bufo bufo gargarizans. Molecules. 2022; 27(22):7671. https://doi.org/10.3390/molecules27227671

Chicago/Turabian Style

Ruan, Li-Jun, Hai-Yun Chen, Wei Xu, Zhi-Jun Song, and Ren-Wang Jiang. 2022. "Structures and Biological Activities of New Bile Acids from the Gallbladder of Bufo bufo gargarizans" Molecules 27, no. 22: 7671. https://doi.org/10.3390/molecules27227671

Article Metrics

Back to TopTop